JBH-492
- Generic Name
- JBH-492
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT04240704
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath